Social Media Ideas for Jagx

Jaguar Health, Inc. (JAGX) Q1 2026 Earnings Call Prepared Remarks Transcript

Jaguar Health (JAGX) Q3 2025 Earnings Transcript

Image source: The Motley Fool. DATENov. 17, 2025, 9 a.m. ETCALL PARTICIPANTSFounder, President, and Chief Executive Officer — Lisa ConteChief Financial Officer — Carol LizakNeed a...

Jaguar Health (JAGX) Q3 2025 Earnings Transcript

Image source: The Motley Fool. DATENov. 17, 2025, 9 a.m. ETCALL PARTICIPANTSFounder, President, and Chief Executive Officer — Lisa ConteChief Financial Officer — Carol LizakNeed a...

Jaguar Health Compliant with Nasdaq Bid Price Rule

JAGX's securities continue to be listed and traded on Nasdaq

Jaguar Health Announces Plan to Explore Strategic Alternatives Aligned with Targeted NDA Filing for Rare Disease Intesti...

Reminder: Lisa Conte, Jaguar's founder & CEO, to present on June 24, 2026 at the Life Sciences Virtual Investor Forum to provide updates on company's crofelemer development pro...

Jaguar Health Reports First Quarter 2026 Financials

Net revenue increased 816% in Q1 2026 vs. Q1 2025, and increased 527% in Q1 2026 vs. Q4 2025, buoyed by license of U.S. commercial rights for Mytesi® and Canalevia®-CA1Company cont...

Jaguar Health Presenting June 24, 2026 at the Life Sciences Virtual Investor Forum to Provide Updates on Company's Crofe...

Click here to register for eventTo access the replay of the June 10, 2026 presentation by Lisa Conte, Jaguar's founder, president & CEO, at the Emerging Growth Conference, clic...

Jaguar Health Announces Conversion of Series O Convertible Preferred Stock Issued as Recent One-time Stock Dividend

Company remains sharply focused on its ongoing global development program for crofelemer for rare intestinal failure diseasesReminder: Two crofelemer presentations in pediatric int...

Jaguar Health to Hold Investor Webcast May 26 Regarding Q1 2026 Financials & Corporate Updates; Jaguar CEO Lisa Cont...

Click here to register for Jaguar's May 26 webcast; Click here to register for May 28 virtual presentation at Lytham Partners ConferenceCompany plans to file its Earnings Report on...

Jaguar Health Reports Approval of All Proposals at 2026 Annual Meeting of Stockholders

Lisa Conte, Jaguar's founder, president & CEO, presenting virtually on June 10, 2026 at the Emerging Growth Conference; click here to register

Jaguar Mining: Low Capex Route To Double Production

Jaguar Health Research in Ethnobotanical Medicine Helps Advance Crofelemer Development for Genetically Defined Rare Cong...

Crofelemer delayed-release tablets are Jaguar's FDA-approved prescription drug under botanical guidance ("botanical drug") derived from the Croton lechleri tree. Crofelemer, in a n...

Jaguar Health Completes Submission of New Animal Drug Application for Full FDA Approval of Crofelemer for Treatment of C...

Jaguar's recently completed pivotal effectiveness study of crofelemer for the treatment of CID in dogs demonstrates positive, statistically significant results

Vinyl Group Ltd (JAXAF) Vinyl Group Ltd, - M&A Call - Slideshow

Jaguar Health Announces Active Treatment Only Continuation of Pivotal Multicenter Clinical Trial in Pediatric Patients w...

First MVID patient enters the active treatment only extension phase after completion of randomized double-blind crossover period to evaluate longer-term safety and efficacy with li...

Jade Biosciences, Inc. (JBIO) Discusses Positive Interim Results From JADE101 Phase I Healthy Volunteer Study and Develo...

Jaguar Mining Inc. Annual General Meeting of Shareholders Voting Results

This small-cap pharma stock jumps 14% amid strategic entry into hospital segment; details here

"The proposed acquisition marks Jagsonpal's strategic entry into the hospital segment and is aligned with the Company's long-term vision of strengthening its presence in India's gr...

Jaguar Mining Inc. Accelerates 5-Year Exploration Plan with Tier 1 Drilling Partnerships

- 5-year plan allows for +227,000 meters of drilling with an estimated expenditure of US$43 million

Lilly scores early positive data for new JAK drug

Acquired through its purchase of Ajax, the drug showed encouraging effects in patients with hard-to-treat myelofibrosis. To analysts, such results could lead to competition for Inc...

Tango Therapeutics, Inc. (TNGX) Discusses Promising Clinical Results for Vopimetostat and Pan-RAS Inhibitor Combination...

Lilly’s Newly Acquired Drug Shows Promise as Next-Gen Blood Cancer Med

Eli Lilly presented encouraging Phase 1 results for AJ1-11095 at the European Hematology Association (EHA) annual meeting in Stockholm. The drug, a type II JAK2 inhibitor in develo...

Form 4 Jade Biosciences Inc For: 11 June

World Markets Watchlist: June 15, 2026